UPDATE 1-Early use of J&J's Zytiga extends prostate cancer survival

CHICAGO, June 3 (Reuters) - Adding Johnson & Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results.

by reutersCOMPANYNEWS via Endless Supplies .Biz - News